Objective To explore the correlation between anemia and the pathogenesis and prognosis of patients with lung cancer. Methods From January 2013 to December 2014, 257 patients with primary lung cancer who were firstly treated at the First Affiliated Hospital of Anhui Medical University were retrospectively analyzed. The clinical data of the patients were collected and the patients were divided into anemia group and control group. The relationship of gender, age, and pathogenesis with anemia was analyzed by x 2 test. Survival analysis was evaluated by Kaplan-Meier and Log-rank test. Results The TNM stage, lymph nodes and remote metastasis , and ECOG score between the two groups were statistically different (x 2 values were 7.94, 4.97, 4.69, 9.02, all P< 0.05). The survival of the two groups showed statistical differences (x2=7.02, P=0.008). Conclusion Anemia might be correlated with the stage, lymph nodes and remote metastasis, ECOG score and prognosis of patients with lung cancer.

Acquired resistance of EGFR-TKIs has become the major limitation of the efficacy of targeted therapy for lung cancer. Lung cancer has been treated by traditional Chinese medicine (TCM) combined with EGFR-TKIs, which originated from clinic. In recent years, reversing research has been conducted based on clinic application to discuss TCM intervening, improving and reversing EGFR-TKIs acquired resistance becoming a novel target for research. This article reviewed mechanism and effects of TCM herbs and compounds’ with the efficacy of clearing away heat and toxic materials, promoting blood circulation to remove blood stasis strengthening the body resistance, and invigorating the circulation of blood, and proposed that the whole regulation and targeted therapy of TCM may carry out synergistic effect and become innovation treatment model for lung cancer.

Incisional hernia is open a major postoperative complication that abdominal surgery remains. The incision type, suture technique, and the choice of primary suture materials are the main factors affecting wound healing. Prophylactic subfascial non-absorbable mesh can be used in high-risk patients to prevent in-cisional hernia.

Intermedin can promote tumor angiogenesis through a variety of signaling pathways. Hypoxia of tumor cells can induce an increased expression of intermedin. Recently, there have been a surge of researches on the relation between intermedin and tumor initiation, progression and metastasis. Intermedin may be a new target for tumor therapy.

Endothelin-1 (ET-1) was characterized as a powerful vasoconstrictor and mitogen for smooth muscle. ET-1 binds to two types of receptors: ET_ A-R and ET_ B-R. Pulmonary arterial hypertension (PH) is a severe condition characterized by a progressive increase in pulmonary vascular resistance. The Endothelial dysfunction plays an important role in the development of pulmonary arterial hypertension. PH can be treated by antagonism of ET-1.

Objective To investigate the expression of intermedin (IMD) in plasma and tissues of lung cancer patients compared with control group and to explore the relationship of IMD with the stage and pathological type of lung cancer. Methods The content of IMD in plasma of 88 lung cancer patients measured using ELISA, 36 lung cancer tissue using immunohistochemistry, compared with control groups. Results Healthy control group IMD level [(38.68±12.65) pg/ml] was lower than lung cancer group [(81.61 ± 30.78) pg/ml] (t =-5.818, P <0.05); There was no significant difference of IMD between small cell [(68.61 ± 30.01) pg/ml] and non-small cell lung cancer [(75.51 ±32.74) pg/ml] (t =-0.680, P >0.05); IMD in stage Ⅳ is higher than stage Ⅰ - Ⅲ (t =-3.444, -3.093, -3.955, P <0.05); IMD with distant metastasis is significantly higher than that without distant metastasis (t =8.052, P =0.000). IMD expression in lung cancer tissues [23/36 (63.9 %)] is significantly higher than adjacent tumor tissues [5/21 (23.8 %)] (x2= 8.525, P <0.05). IMD in Stage Ⅲ[14/17(82.4 %)] is significantly higher than in stage Ⅰ [1/5 (20.0 %)] (x2 = 6.924, P =0.009). Conclusion The expression of IMD in lung cancer patients is significantly higher than control groups. Expression has correlation with stage and metastasis, which might play a vital role in the pathogenesis of lung cancer.

Pancreatic cancer was one of common malignant tumors of the digestive tract, early diagnosis of which was difficult and surgical resection rate was low. The prognosis was poor, and its incidence increased year by year. Conventional treatment of pancreatic cancer includes surgery, radiotherapy and chemotherapy, but 90％ of the patients had lost the surgical opportunity when they see a doctor, and not sensitive to radiotherapy and chemotherapy. Relative to these traditional treatments, gene therapy is an innovative approach for the treatment of pancreatic cancer and had attracted wide attention in recent years. Many gene therapy drugs for pancreatic cancer had now entered Ⅰ / Ⅱ clinical trials. The gene therapy techniques for pancreatic cancer included antisense gene therapy, suicide gene therapy, immune gene therapy, and oncolytic virus therapy. In this article, we reviewed recent advances in gene therapy for pancreatic cancer.

Surgery in combination with chemotherapy and radiotherapy is the standard of lung cancer treatment,but postoperative recurrence is very common which usually leads to higher mortality and lower life quality. Immunotherapy on post-operative patients fully mobilizes the body's defense mechanisms,activates the immune cells,and kills residual cancer cells. Current research on lung cancer immunotherapy mainly includes four categories:adoptive immunotherapy,dendritic cell vaccine,non-specific antigen immune therapy and anti-gen-specific vaccine. These studies show lung cancer immunotherapy intervention can effectively reduce postop-erative residual cancer cells,reduce postoperative recurrence rate,prolong survival,significantly improve the prognosis,and is worth spreading in clinical practice.

Glutamine is a conditionally essential amino acid. With the further researches on Glutamine, most of the studies demonstrated that glutamine supplements may reduce the severity of side effects and increases the selectivity of therapy for the tumor in oncology therapy while enhancing immune function. Glutamine supplements is safe and effective in cancer therapy, having a good application prospect.

Melanoma-associated antigen MAGE-A3 is expressed in various types of tumors,but not in normal cells except testis and placenta.MAGE-A3 can be presented by both HLA class I and HLA class II molecules after being processed into antigen peptide.MAGE-A3 has recently been widely used in the diagnosis and immunotherapy of tumors.This article reviews the applications of MAGE-A3 in the diagnosis and immunotherapy of tumors.